CSPIA
NAGE

Cary Street Partners Investment Advisory’s Niagen Bioscience NAGE Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-250
Closed -$365 – 1834
2023
Q3 		$365 Hold
250
– – ﹤0.01% 1804
2023
Q2 		$393 Hold
250
– – ﹤0.01% 1697
2023
Q1 		$383 Hold
250
– – ﹤0.01% 1619
2022
Q4 		$420 Buy
+250
New +$396 ﹤0.01% 1625

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cary Street Partners Investment Advisory's NAGE Position: Q4 2023 in Review

Cary Street Partners Investment Advisory sold out of Niagen Bioscience (NAGE) in Q4 2023, closing a stake of 250 shares — an estimated $365 sold.

Cary Street Partners Investment Advisory first reported a position in NAGE in Q4 2022 and held it in 4 quarters. The position peaked at $420 in Q4 2022. 53 funds tracked by Wall St. Rank hold NAGE as of Q4 2023.

  • Cary Street Partners Investment Advisory reported no remaining Niagen Bioscience position as of Q4 2023 after selling out during the quarter.
  • Cary Street Partners Investment Advisory sold 250 Niagen Bioscience shares in Q4 2023, an estimated $365.
  • Cary Street Partners Investment Advisory first reported a position in Niagen Bioscience in Q4 2022 and held it in 4 quarters.
  • Cary Street Partners Investment Advisory's Niagen Bioscience position peaked at $420 in Q4 2022.
  • 53 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2023.

Based on Cary Street Partners Investment Advisory's 13F filing for Q4 2023, filed 5 Feb 2024.